

SINGAPORE
BIOTECH INVEST

21-22 March 2017

Singapore Exchange (SGX)

HONG KONG
BIOTECH INVEST

23-24 March 2017

KPMG Hong Kong

AUSTRALIA-CHINA
BIOTECH INVEST

27-28 March 2017

Shanghai Marriott Hotel City Centre

Bo Liu, PhD, MBA

Bo is the Principal of Venture Investments of Johnson & Johnson Innovation – JJDC, Inc. (JJDC). He is based in Shanghai, China and focuses on the life science investment opportunities in Asia Pacific regions.

Prior to joining JJDC, Bo was Director of Business Development and Strategic Planning with GlaxoSmithKline Consumer Healthcare China, where he led key strategic initiatives in mergers and acquisitions, licensing and portfolio optimization. Prior to GSK, he worked in the corporate development and strategy group with Charles River Laboratories in Boston, where he played an instrumental role in several strategic transactions. Bo has executed many M&A, licensing and venture investment transactions in the US, Europe and Asia Pacific.

Bo received a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago, and a Master of Medicine from the seven-year program of Tongji Medical University in Wuhan, China. He received residency training in Urology at Union Hospital of Tongji Medical University.

